Clinical Trial Update: Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias [Phase 2]

View source ↗

Summary

Phase 2 study of bosutinib (SKI-606) in Philadelphia chromosome-positive leukemias, including chronic myeloid leukemia, completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• BOSULIF (bosutinib)

Snippet

Sponsor: Pfizer | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2013-03-12